Post Profile

Novel 'patient-friendly' colonoscopy prep shows excellent efficacy and safety

(Bioscribe) Detailed results from a Phase 2 study of a novel colonoscopy prep (ECP) under development by ColonaryConcepts, LLC show the investigational treatment to be at least as effective and safe as two currently available colonoscopy prep formulations, while offering a much higher level of patient satisfaction and preference than standard preps.
read more


Related Posts

Phase 2 Study Of SKP-1041 For Sleep Maintenance Insomnia Shows Significant Reduction Of Mid-Night Awakenings Without Next-Day Cognitive Impairment

Health : Medical News Today

Results of a Phase 2 study sponsored by Somnus Therapeutics, Inc., add further evidence supporting the efficacy and safety of a novel bedtime therapeutic that addresses a major underserved need of insomnia patients: maintaining slee...

Novel Cancer Drug Proves Safe for Leukemia Patients in Phase I Clinical Trial

Health : Newswise Medical News

Results of a Phase I clinical trial showed that a new drug targeting mitochondrial function in human cancer cells was safe and showed some efficacy. The findings, reported by doctors at Wake Forest Baptist Medical Center, are publis...

Phase 3 results demonstrate safety and efficacy profile of Invokana (canagliflozin) as add-on therapy for type 2 diabetes in adults

Health : Medical News Today

Janssen Research & Development, LLC (Janssen) have announced results from a new 52-week analysis of Phase 3 results showing INVOKANA® (canagliflozin) provided substantial improvements in glycemic control in patients with type 2 diab...

Neurim Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results Of Piromelatine For The Treatment Of Insomnia

Health : Medical News Today

Neurim Pharmaceuticals have announced positive results from a phase II clinical study evaluating the efficacy and safety of Piromelatine (Neu-P11), a novel investigational multimodal sleep medicine developed for the treatment of pat...

Abbott Reports Interim Results From Phase III Open-Label Study Of Investigational Treatment For Advanced Parkinson's Disease

Health : Medical News Today

Interim efficacy and safety results from a long-term, 54-week, Phase III open-label study of Abbott's investigational treatment for advanced Parkinson's disease showed that patients treated with levodopa-carbidopa intestinal gel (LC...


Copyright © 2016 Regator, LLC